Avid Radiopharmaceuticals
Ximin Li currently serves as the Sr. Director at Avid/Eli Lilly since October 2022 and has held the position of Principal Research Scientist at Avid/Eli Lilly & Co. since March 2018. With a tenure at Avid Radiopharmaceuticals starting in October 2009, Ximin Li has contributed as a Senior Research Chemist and previously as a Research Chemist, focusing on the development of novel PET radiotracers for neurodegenerative diseases. Prior experience includes a role as a Postdoctoral Research Associate at the University of Pennsylvania, specializing in the synthesis of complex organic compounds, and as a Research Scientist at Red Sun Group Corporation, where supervision of research specialists and chemical engineers was part of the responsibility. Ximin Li obtained a Postdoc in Organic Chemistry from the University of Pennsylvania, a Ph.D. from Washington University in St. Louis, and a BS and MS in Chemistry from Nanjing University of Science and Technology.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.